Skip to content

The effect of non-invasive temporal interference stimulation on patients with Parkinson's disease

The effect of non-invasive temporal interference stimulation on patients with Parkinson's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084797
Enrollment
Unknown
Registered
2024-05-24
Start date
2024-05-24
Completion date
Unknown
Last updated
2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Experimental-control group:Participants received TI stimulation at the first time, and received sham stimulation at the second time, with a 7-day interval between the two stimulation.
Control-experimental group:Participants received sham stimulation at the first time, and received TI stimulation at the second time, with a 7-day interval between the two stimulation.

Sponsors

School of Exercise and Health, Shanghai University of Sport
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Adult male or female, aged 40 years or older; (2) Diagnosis of idiopathic Parkinson's disease according to the Brain Bank criteria, with onset after 40 years of age; (3) Response to levodopa-based drugs; (4) Hoehn and Yahr (H&Y) Stage 1.5-2.5; (5) Ability to walk alone for at least five minutes without the use of assistive devices; (6) No occurrence of severe Freezing Of Gait (FOG).

Exclusion criteria

Exclusion criteria: (1) Presence of other central neurological disease affecting the experiment; (2) Mild or greater cognitive impairment, as indicated by a MoCA score of =23; (3) Orthopedic or other health conditions that may affect gait or balance; (4) MRI contraindications such as claustrophobia; (5) A history of antipsychotic medication, antidepressant medication, or other medications that may affect dopamine levels; (6) History of antipsychotic, antidepressants, or other medication usage that may affect dopamine levels, or a history of other severe psychiatric illnesses; (7) Metal implants in the head or heart; (8) A history of electroshock; (9) Ongoing participation in other gait and balance-related interventions; (10) Physician-diagnosed risk factors for cardiovascular exercise.

Design outcomes

Primary

MeasureTime frame
Movement Disorder Society Unified Parkinson’s Disease Rating Scale Part III;brain activation and network functional connectivity;Blinding and adverse events questionnaire;

Secondary

MeasureTime frame
Movement Disorder Society Unified Parkinson’s Disease Rating Scale Part II;Montreal Cognitive Assessment;Time up and go tests;amplitude of low-frequency fluctuations;regional homogeneity;Balance biomechanical index;Gait biomechanical index;Dual-task cost;

Countries

China

Contacts

Public ContactYu Liu

Shanghai University of Sport

yuliu@sus.edu.cn+86 21 6550 7351

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026